Introduction
============

Positron emission tomography (PET) is widely used for cancer detection, staging and monitoring the response to therapy. \[^18^F\] fluorodeoxyglucose (^18^F-FDG) and 3′-deoxy-3′-\[^18^F\] fluorothymidine (^18^F-FLT) are commonly used PET tracers for imaging glucose metabolism and cell proliferation, respectively ([@b1-ol-0-0-6840]--[@b12-ol-0-0-6840]). In a mouse model of human lung cancer, it has been previously demonstrated that intratumoral distribution between ^18^F-FLT and ^18^F-FDG was mutually exclusive. ^18^F-FLT accumulated primarily in proliferating cancer cells, whereas ^18^F-FDG accumulated in hypoxic cancer cells that are less proliferative ([@b13-ol-0-0-6840]--[@b16-ol-0-0-6840]). To the best of our knowledge, intratumoral distribution of ^18^F-FLT and ^18^F-FDG in patients with lung cancer has not been previously reported.

Differential diagnosis of malignant pulmonary lesions may be challenging. Computed tomography (CT) is the method of choice for the diagnosis of pulmonary lesions. PET/CT imaging reflects the biological and metabolic aspects of pulmonary lesions ([@b17-ol-0-0-6840]). ^18^F-FDG PET/CT has been widely used for the diagnosis of pulmonary lesions; however, false-negative as well as false-positive results are frequently observed ([@b17-ol-0-0-6840],[@b18-ol-0-0-6840]). ^18^F-FLT is a positron radioactive tracer that reflects cancer cell proliferation. Therefore, ^18^F-FLT may be a useful tool for the diagnosis of pulmonary lesions ([@b19-ol-0-0-6840]).

In the present study, it was hypothesized that the mutually exclusive distribution pattern between ^18^F-FLT and ^18^F-FDG described in animal tumor models may apply to patients with lung malignancies as well. To examine this hypothesis, patients with pulmonary lesions that initially underwent a ^18^F-FDG PET/CT scan and subsequently a ^18^F-FLT PET/CT scan were studied.

Materials and methods
=====================

### Patients

The present study was approved by the Institutional Review Boards of the Inner Mongolia Medical University (Hohhot, China) and the Soochow Medical University (Jiangsu, China). Written informed consent was obtained from all patients prior to participation. The Institutional Review Board of the University of Louisville (Louisville, KY, USA) approved data transfer and use. From June 2013 to August 2015, a total of 55 patients ([Table I](#tI-ol-0-0-6840){ref-type="table"}) with pretreated lung lesions were recruited to the present study (31 males and 24 females; age range, 17--68 years). Histological examination of the lesions was performed in every patient. The diameter of the lesions ranged between 8 and 50 mm.

### Radiopharmaceuticals

\[^18^F\] fluoride was generated in-house using a cyclotron. ^18^F-FDG and ^18^F-FLT were synthesized automatically using FX-FN conventional modules at the PET/CT facility of the Inner Mongolia Medical University (Hohhot, China). ^18^F-FDG and ^18^F-FLT were pyrogen-free and qualified for clinical use, with radiochemical purity \>98%.

### PET/CT imaging protocol

PET/CT images were obtained using a GE Discovery ST PET/CT scanner. Prior to ^18^F-FDG PET scanning, patients were instructed to fast for \>6 h and their blood glucose levels were determined to be \<6 mmol/l. Whole body ^18^F-FDG PET/CT scans were performed 1 h after intravenous administration of 3.7 MBq/kg ^18^F-FDG. Subsequently, 3 days after ^18^F-FDG imaging, local thoracic ^18^F-FLT PET/CT scans were performed, 1 h after the injection of ^18^F-FLT (3.7 MBq/kg). Spiral CT scans (voltage, 120 kV; current, 160--220 mA) were conducted for attenuation correction and anatomy referral.

A board of three certified physicians in nuclear medicine assessed the PET/CT images. Visual analysis to score lesion radioactivity uptake of each tracer was performed ([@b20-ol-0-0-6840]). The maximal standardized uptake value (SUV~max~) was used to spatially compare the intralesional distribution of ^18^F-FDG and ^18^F-FLT.

Histological examination of the lesions was performed for all patients by board-certified pathologists at the Department of Pathology (Affiliated Hospital of Inner Mongolian Medical University). Routine hematoxylin and eosin (H&E) staining was performed. Briefly, slides containing 5 µm paraffin sections were placed on a slide holder, deparaffinized and rehydrated. Sections were treated with hematoxylin solution, dipped 8--12 times in acid ethanol to destain, and stained for 30 sec with eosin. H&E stain imaging was developed with a light microscope at ×100 magnification.

### Statistical analysis

SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA) was used to analyze the data using a χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

The clinical information and PET/CT results of the patient cohort are summarized in [Table I](#tI-ol-0-0-6840){ref-type="table"}. Among the 55 cases, 24 lesions were confirmed as primary lung malignancies (16 cases with adenocarcinoma, 8 cases with squamous cell carcinoma) and 31 lesions were benign (18 cases with tuberculosis, 5 with hamartoma, 4 with inflammatory pseudo-tumor and 4 with organizing pneumonia).

Spatial intratumoral distribution of ^18^F-FLT and ^18^F-FDG mismatched in 19/24 malignant lesions (79%) and matched in 5 (21%). [Fig. 1](#f1-ol-0-0-6840){ref-type="fig"} presents an apparent mismatch in intratumoral distribution of ^18^F-FLT and ^18^F-FDG in a 67-year-old male patient with pretreated lung adenocarcinoma. Increased ^18^F-FDG uptake combined with decreased ^18^F-FLT accumulation in a patient with squamous carcinoma is presented in [Fig. 2](#f2-ol-0-0-6840){ref-type="fig"}. Intratumoral distribution of ^18^F-FLT and ^18^F-FDG in lung malignancies was identified to be mainly heterogeneous and mutually excluded.

Regarding the 31 benign lesions, intralesional mismatched distribution of ^18^F-FLT and ^18^F-FDG was observed in 12 cases (39%). [Fig. 3](#f3-ol-0-0-6840){ref-type="fig"} presents scan images of mismatched ^18^F-FLT and ^18^F-FDG intralesional distribution in a 49-year-old male patient with lung tuberculoma. Matched intralesional distribution of ^18^F-FLT and ^18^F-FDG was observed in 19/31 benign lesions (61%). An indicative example of a patient with an inflammatory pseudotumor demonstrating negative ^18^F-FLT and positive ^18^F-FDG PET scans is presented in [Fig. 4](#f4-ol-0-0-6840){ref-type="fig"}.

These results indicate that mismatched intralesional accumulation of ^18^F-FLT and ^18^F-FDG was more frequently observed in malignant compared with benign lung lesions. The difference in intralesional distribution of ^18^F-FLT and ^18^F-FDG between malignant and benign lesions was statistically significant (P\<0.05).

Discussion
==========

It has previously been reported based on studies using mouse non-small cell lung cancer models that ^18^F-FDG accumulates in hypoxic regions, whereas ^18^F-FLT accumulates in well-oxygenated proliferating cells. Additionally, it has been demonstrated that the intratumoral distribution of ^18^F-FDG and ^18^F-FLT is mutually exclusive ([@b13-ol-0-0-6840],[@b14-ol-0-0-6840]). In the present study, the association between ^18^F-FDG and ^18^F-FLT uptake was further elucidated in patients with lung cancer.

In the present study, it was demonstrated that intratumoral ^18^F-FDG and ^18^F-FLT accumulation is mutually exclusive. It was observed that regions with increased ^18^F-FDG accumulation were mainly associated with decreased ^18^F-FLT uptake. This is consistent with previous preclinical results in mouse lung cancer models ([@b13-ol-0-0-6840]--[@b16-ol-0-0-6840]). Intratumoral heterogeneity of ^18^F-FDG and ^18^F-FLT accumulation reflected the heterogeneous distribution of hypoxic (increased ^18^F-FDG uptake) and highly proliferative (increased ^18^F-FLT uptake) cancer cells; in agreement with previously reported preclinical results ([@b13-ol-0-0-6840]--[@b16-ol-0-0-6840]).

^18^F-FDG PET/CT is widely used in clinical practice for the detection of malignancies. However, it is not a cancer-specific tracer as it accumulates in hypoxic tissues regardless of malignant phenotype ([@b10-ol-0-0-6840],[@b13-ol-0-0-6840],[@b15-ol-0-0-6840]). Even though benign lesions present mainly low ^18^F-FDG uptake, in certain cases increased ^18^F-FDG accumulation is observed in inflammatory diseases including tuberculosis. Activated macrophages and other inflammatory cells may result in enhanced ^18^F-FDG accumulation in benign conditions including pneumonia, bronchiectasis, pulmonary tuberculosis, fungal infections, sarcoidosis, histoplasmosis and granuloma ([@b21-ol-0-0-6840],[@b22-ol-0-0-6840]). Macrophages and other inflammatory cells, frequently observed in necrotic regions of inflammatory lesions, accumulate increased levels of ^18^F-FDG possibly due to the hypoxic microenvironment ([@b23-ol-0-0-6840]).

In the present study, ^18^F-FDG and ^18^F-FLT PET/CT scan uptake, performed with a 3-day interval, were compared in patients with lung lesions. A mismatch in the intralesional ^18^F-FLT and ^18^F-FDG accumulation was observed particularly in lung malignancies compared with benign lesions ([Table I](#tI-ol-0-0-6840){ref-type="table"}). Therefore, on the basis of the results of the present study, it is suggested that this mismatch may serve as an indicator of lung malignancy.

In well-differentiated slow-growing tumors, including bronchiole alveolar carcinomas, false-negative ^18^F-FDG PET results have been reported ([@b20-ol-0-0-6840],[@b24-ol-0-0-6840]). This may be attributed to to the absence of hypoxic microenvironment of slow-growing malignancies"^18^F-FDG is mainly considered as a hypoxia-specific rather than a tumor avid tracer ([@b13-ol-0-0-6840],[@b15-ol-0-0-6840],[@b16-ol-0-0-6840]). This explains why ^18^F-FDG exhibited relatively low specificity in distinguishing malignant from benign lesions.

It has been demonstrated that the combination of ^18^F-FLT and ^18^F-FDG, either as separate PET scans performed on subsequent days or as one scan using a ^18^F-FLT and ^18^F-FDG cocktail, may be superior to an ^18^F-FDG scan for accurate disease detection ([@b14-ol-0-0-6840]). ^18^F-FDG mainly accumulates in hypoxic regions, whereas ^18^F-FLT accumulates in highly proliferating cells ([@b6-ol-0-0-6840],[@b7-ol-0-0-6840],[@b13-ol-0-0-6840],[@b14-ol-0-0-6840]). The use of ^18^F-FLT and ^18^F-FDG cocktail PET may have an advantage compared with individual tracer PET. A clinical trial for ^18^F-FLT and ^18^F-FDG cocktail PET scanning for cancer detection and management is currently underway ([@b25-ol-0-0-6840]).

The results of the present study demonstrate that mismatched intratumoral distribution of ^18^F-FLT and ^18^F-FDG is a common feature of patients with lung cancer and may serve as an indicator of lung malignancy.
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![Scan images of a 67-year-old male patient with pretreated adenocarcinoma (39×23 mm) in the right middle lobe of the lung. An ^18^F-FLT PET/CT scan was performed 3 days after an ^18^F-FDG scan. (A) ^18^F-FDG PET/CT scan image. (B) ^18^F-FLT PET/CT scan image. (C) CT scan providing additional anatomical information. (D) Enlarged ^18^F-FDG scan image of the area indicated by the arrow. (E) Enlarged ^18^F-FLT scan image of the area indicated by the arrow. (F) Hematoxylin and eosin staining indicated lung adenocarcinoma. PET/CT, positron emission tomography-computed tomography; ^18^F-FLT, 3′-deoxy-3′-\[^18^F\] fluorothymidine; ^18^F-FDG, \[^18^F\] fluorodeoxyglucose; R, right.](ol-14-05-5279-g00){#f1-ol-0-0-6840}

![Scan images of a 49-year-old male patient with pretreated squamous carcinoma (30×17 mm) in the left upper lobe in the lung. An ^18^F-FLT PET/CT scan was performed 3 days after an ^18^F-FDG scan. (A) ^18^F-FDG PET/CT scan image. (B) ^18^F-FLT PET/CT scan image. (C) CT scan providing additional anatomical information. (D) Enlarged ^18^F-FDG scan image of the area indicated by the arrow. (E) Enlarged ^18^F-FLT scan image of the area indicated by the arrow. (F) Hematoxylin and eosin staining indicated squamous carcinoma. PET/CT, positron emission tomography-computed tomography; ^18^F-FLT, 3′-deoxy-3′-\[^18^F\] fluorothymidine; ^18^F-FDG, \[^18^F\] fluorodeoxyglucose; R, right.](ol-14-05-5279-g01){#f2-ol-0-0-6840}

![Scan images of a 49-year-old male patient with untreated tuberculoma (13×18 mm) in the right upper lobe in the lung. An ^18^F-FLT PET/CT scan was performed 3 days after an ^18^F-FDG scan. (A) ^18^F-FDG PET/CT scan image. (B) ^18^F-FLT PET/CT scan image. (C) CT scan providing additional anatomical information. (D) Enlarged ^18^F-FDG scan image of the area indicated by the arrow. (E) Enlarged ^18^F-FLT scan image of the area indicated by the arrow. (F) Hematoxylin and eosin staining indicated tuberculoma. PET/CT, positron emission tomography-computed tomography; ^18^F-FLT, 3′-deoxy-3′-\[^18^F\] fluorothymidine; ^18^F-FDG, \[^18^F\] fluorodeoxyglucose; R, right.](ol-14-05-5279-g02){#f3-ol-0-0-6840}

![Scan images of a 59-year-old female patient with inflammatory pseudotumor (50×40 mm) in the right upper lobe in the lung. An ^18^F-FLT PET/CT scan was performed 2 days after an ^18^F-FDG scan. (A) ^18^F-FDG PET/CT scan image. (B) ^18^F-FLT PET/CT scan image. (C) CT scan providing additional anatomical information. (D) Enlarged ^18^F-FDG scan image of the area indicated by the arrow. (E) Enlarged ^18^F-FLT scan image of the area indicated by the arrow. (F) Hematoxylin and eosin staining indicated inflammatory pseudotumor. PET/CT, positron emission tomography-computed tomography; ^18^F-FLT, 3′-deoxy-3′-\[^18^F\] fluorothymidine; ^18^F-FDG, \[^18^F\] fluorodeoxyglucose; R, right.](ol-14-05-5279-g03){#f4-ol-0-0-6840}

###### 

Patients\' clinical data and PET/CT results.

  Patient no.   Age/sex   SUV~max~ FDG/FLT   Pathological diagnosis     FDG/FLT PET/CT SUVmax
  ------------- --------- ------------------ -------------------------- -----------------------
    1           55/F      5.3/2.7            Adenocarcinoma             Mismatch
    2           48/F      3.5/1.4            Tuberculoma                Match
    3           61/F      4.2/2.1            Squamous carcinoma         Match
    4           65/F      2.8/1.1            Tuberculoma                Mismatch
    5           59/F      2.3/1.0            Organizing pneumonia       Match
    6           63/F      5.8/2.1            Adenocarcinoma             Mismatch
    7           60/F      2.3/1.2            Tuberculoma                Mismatch
    8           62/F      4.8/2.2            Adenocarcinoma             Mismatch
    9           64/F      3.2/2.0            Adenocarcinoma             Mismatch
  10            64/F      1.6/0.9            Tuberculoma                Mismatch
  11            67/F      1.9/0.9            Hamartoma                  Match
  12            49/F      2.1/1.5            Tuberculoma                Match
  13            57/F      3.8/2.8            Adenocarcinoma             Mismatch
  14            59/F      4.1/2.6            Adenocarcinoma             Mismatch
  15            47/F      2.0/1.4            Tuberculoma                Match
  16            49/M      2.6/1.6            Tuberculoma                Mismatch
  17            53/M      3.7/2.4            Adenocarcinoma             Mismatch
  18            60/M      7.9/2.8            Squamous carcinoma         Match
  19            65/M      1.5/0.9            Organizing pneumonia       Match
  20            67/M      3.5/2.0            Inflammatory pseudotumor   Mismatch
  21            57/M      6.8/2.4            Squamous carcinoma         Match
  22            60/M      3.7/2.6            Squamous carcinoma         Match
  23            58/M      4.2/2.0            Squamous carcinoma         Mismatch
  24            62/M      3.6/2.5            Adenocarcinoma             Mismatch
  25            63/M      3.4/2.6            Adenocarcinoma             Mismatch
  26            66/M      1.8/1.0            Inflammatory pseudotumor   Mismatch
  27            45/M      1.6/1.3            Tuberculoma                Mismatch
  28            59/M      2.6/1.2            Tuberculoma                Match
  29            17/M      2.9/1.5            Tuberculoma                Match
  30            48/M      3.0/1.8            Squamous carcinoma         Mismatch
  31            62/M      1.1/1.0            Tuberculoma                Match
  32            62/M      2.4/1.6            Tuberculoma                Match
  33            62/M      2.1/0.8            Organizing pneumonia       Mismatch
  34            50/M      3.1/0.9            Tuberculoma                Match
  35            52/M      1.5/1.0            Hamartoma                  Match
  36            57/M      3.6/2.2            Adenocarcinoma             Mismatch
  37            54/M      3.2/1.9            Adenocarcinoma             Mismatch
  38            52/M      1.6/0.7            Tuberculoma                Match
  39            44/M      1.0/0.7            Hamartoma                  Mismatch
  40            49/M      5.4/1.8            Squamous carcinoma         Mismatch
  41            62/M      1.5/0.7            Tuberculoma                Match
  42            68/M      3.5/2.0            Adenocarcinoma             Mismatch
  43            47/F      4.1/1.1            Tuberculoma                Match
  44            49/M      3.1/1.4            Tuberculoma                Match
  45            58/M      6.8/2.4            Squamous carcinoma         Mismatch
  46            60/M      2.6/1.1            Tuberculoma                Mismatch
  47            67/M      8.2/3.5            Adenocarcinoma             Mismatch
  48            55/F      3.2/1.8            Adenocarcinoma             Match
  49            48/F      1.5/1.0            Organizing pneumonia       Mismatch
  50            61/F      5.8/2.5            Adenocarcinoma             Mismatch
  51            65/F      2.7/2.1            Adenocarcinoma             Mismatch
  52            59/F      1.9/0.8            Inflammatory pseudotumor   Match
  53            63/F      1.6/0.8            Hamartoma                  Mismatch
  54            60/F      1.8/1.1            Inflammatory pseudotumor   Match
  55            62/F      1.5/0.9            Hamartoma                  Match

PET/CT, positron emission tomography-computed tomography; FLT, 3′-deoxy-3′-\[^18^F\]fluorothymidine; FDG, \[^18^F\]fluorodeoxyglucose; SUV~max~, maximal standardized update value; F, female; M, male.
